Dasatinib (Sprycel) is a targeted therapeutic drug belonging to the class of kinase inhibitors, primarily used for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).

Precautions for Taking Dasatinib (Sprycel)

Strictly Follow Doctor's Instructions for Medication

Dasatinib must be used under the guidance of a physician with experience in leukemia treatment.

Patients should not change the dosage or adjust the medication regimen without authorization.

Correct Administration Method

The tablets must be swallowed whole; patients must not chew, crush, or split the tablets.

The drug should be taken with a liquid to ensure it enters the body completely.

For pediatric patients with swallowing difficulties, special administration methods may be used, but this must be done under the guidance of a doctor.

Standardized Administration Time

The drug can be administered once daily, either in the morning or evening.

Dasatinib can be taken with food or on an empty stomach, providing patients with a convenient medication option.

Special Dietary Requirements

Avoid drinking grapefruit juice, as grapefruit juice may inhibit the CYP3A4 enzyme, thereby increasing the blood concentration of dasatinib and raising the risk of adverse reactions.

Management of Drug Interactions

When used in combination with potent CYP3A4 inhibitors, the dosage of dasatinib needs to be reduced.

When used in combination with potent CYP3A4 inducers, the dosage of dasatinib needs to be increased.

Risk of Myelosuppression

Dasatinib treatment is associated with severe thrombocytopenia, neutropenia, and anemia.

These hematological adverse reactions occur earlier and more frequently in patients with advanced CML or Ph+ ALL.

For patients with chronic-phase CML, it is recommended to perform a complete blood count (CBC) test every 2 weeks for 12 consecutive weeks, and then every 3 months thereafter.

Medication Monitoring for Dasatinib (Sprycel)

Monitoring of Hematological Parameters

Complete blood count monitoring should be performed regularly. Different monitoring frequencies are established according to the disease stage to ensure timely detection and management of hematological adverse reactions.

Liver Function Monitoring

Evaluate liver function before treatment, and monitor it monthly during treatment or as clinically needed. Pay special attention to changes in transaminase and bilirubin levels.

Electrocardiogram (ECG) Monitoring

Dasatinib may increase the risk of QTc interval prolongation. Hypokalemia or hypomagnesemia should be corrected before administering the drug.

Special Testing Items

Corresponding imaging examinations should be performed based on clinical manifestations, especially when patients present with respiratory symptoms.